Background: The prevalence of obesity has increased dramatically throughout the world, and weight reduction through lifestyle management is urgently warranted. At present, numerous supplements advertised for their antioverweight property are available in the Japanese market, but most of these lack proper evidence. Thus, we investigated dietary supplements that have been tested in clinical trials.
INTRODUCTION
Globally, strategies to prevent the development of obesity are focused on lifestyle modifications that restrict caloric intake and increase physical activity 1 . Therefore, treatments for overweight and obesity have important medical implications. Food research has attracted attention to the potential of natural products as treatments for obesity [1] [2] [3] . These products contain dietary phytochemicals with high potential for health promotion and disease prevention [4] [5] [6] [7] . The antiobesity effects of these compounds are mediated by regulatory effects on various pathways, including lipid absorption, energy intake and expenditure, increased lipolysis, and decreased lipogenesis and differentiation. Dietary supplements have been proposed as stimulants of weight loss that alter body functions during low-calorie dieting. Some agents have anorectic effects that lead to decreased food intake, whereas others affect metabolic changes that cause weight loss by increasing energy output [8] . Complementary and alternative medicines (CAM) have long been used in eastern countries *Address correspondence to this author at the Department of Complementary & Alternative Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita city, Osaka, 565-0871, Japan; Tel: +81-6-6879-3498; Fax: +81-6-6879-3499; E-mail: kaz@cam.med.osaka-u.ac.jp and are increasingly being used worldwide. Supplements for anti-obesity are an established CAM modality and have attracted attention as complementary medicines in recent years. However, rigorous scientific studies of these products are few, and in many cases safety and efficacy are subordinate to marketing.
The Japanese market for supplements recently reached 1.8 trillion yen 2 , and many are advertised for their antioverweight property on the internet and in newspapers. However, most of these lack sufficient evidence for medical professionals to prescribe them to patients with obesity and related complications. Evidence-based research regarding the efficacy and safety of anti-obesity supplements is required to make definite recommendations for lifestyle management. The purpose of this review was to evaluate the efficacy and safety of anti-obesity supplements currently available in the Japanese market.
In this study, we researched data pertaining to ingredients or supplements that are consumed for weight loss. Among marketed supplements in Japan, we only reviewed ingredients for which evidence is available. This review summarizes evidence of the effects and safety of anti-obesity supplements relevant for patients and medical professionals.
MATERIALS & METHODS
We researched anti-obesity supplements in the Japanese market by performing a representative google search in Japanese on September 13, 2013, using the search terms "anti-obesity supplements," "Diet supplements," and "supplements for weight reduction." Although numerous marketed supplements were identified from the initial database search, we focused on best-seller products from databases of popular internet distributers in Japan. In addition, we contacted the major supplement manufacturing company, which markets its products on television. We also performed market research in supermarkets and drug stores.
Some dietary supplements were identified from evidence of current product sales. Manufacturers were contacted for evidence of supplement effects and safety, and evidencebased data for items were requested. However, data from other sources was also included in this study. When multiple products contained the same agent, we chose the most representative product.
We limited the main outcomes of anti-obesity effects to weight and body fat loss. Searches and analyses for impaired glucose tolerance (IGT), insulin resistance (IR) or appetite in participants did not include. All abstracts from human studies of changes in anthropometric measures such as body weight, body mass index (BMI) and body fat were included. Publications of in vitro experiments, review articles, and letters to editors were excluded. Unpublished data were also excluded.
We received responses from 41 of 49 listed companies [9] . Among these, 10 did not have evidence-based data and 2 others had products that lacked anti-obesity efficacy. Then, we excluded 12 products with evidence that was only published in Japanese. We also excluded 6 products that lacked characterization in human studies. Finally, we included 11 products (Table 1) with published clinical evidence of antiobesity effects of their supplements, as described in Table 2 .
RESULTS

Ashitaba (Angelica Keiskei)
Ashitaba is a green and yellow vegetable of the Apiaceae Angelica family and contains a rich balance of vitamin and mineral nutrients. Similar to kale, it is often used as a nutritious food ingredient, but has even higher contents of protein; carotene; potassium; vitamins E, K, and B; pantothenic acid; niacin; and dietary fiber. Zhang et al. (2013) demonstrated that ashitaba contains the two main phytochemicals 4-hydroxyderricin (4HD) and xanthoangelol (XAG) (chemical structures 1), which have various biological effects that lead to anti-tumor, anti-inflammatory, and anti-diabetic activities. 4HD and XAG inhibited differentiation of 3T3-L1 (3T3 is a cell line derived from mouse and used in biological research on adipose tissue) adipocytes by suppressing the expression of cytidine-cytidine-adenosine-adenosinethymidine enhancer-binding proteins (C/EBP)-, C/EBP-, and peroxisome proliferator-activated receptor (PPAR) . These effects lead to activation of AMP-activated protein kinase (AMPK), extracellular Signal-regulated kinase (ERK) 1/2, and c-jun N-terminal kinase (JNK) signaling pathways, indicating potential benefits of ashitaba 4HD and XAG in the prevention of obesity and obesity-related disorders [10] . Ohnogi. et al. (2012) reported that ingestion of ashitaba green juice (6.2 g/day) for 8 wks resulted in significant reduction in visceral fat areas ( 25.5 cm 2 , p < 0.01), body weight ( 1.4 kg, p < 0.05), BMI ( 0.5, p < 0.05), and body fat ( 2.1%, p< 0.01) in nine adult subjects with metabolic syndrome [11] . 
Bofu-tsusho-san (An Oriental Herbal Medicine)
Bofu-tsusho-san (BF), a traditional Japanese herbal medicine "kampo" comprising 18 crude components (Table  3) , has been an effective treatment for obesity, constipation, and hypertension. In a clinical trial, BF reduced body weight and improved glucose tolerance [12] . In addition, several pharmacological studies have reported its ability to counter obesity, fatty liver, and arteriosclerotic diseases [13] . As in traditional Chinese medicine, BF was used to reduce fever after bouts of influenza and promote bowel movements. Af-ter administering BF, it was demonstrated that BF activates the brown adipose tissue (BAT) and promote the lipolysis in white adipose tissue (WAT). Furthermore, reports of thermogenic responses to BF components from Ephedrae herba (EH), Glycyrrhizae radix (GR), Forsythiae fructus (FF), and Schizonepetae spica (SS) extracts have been reported. These inhibit cyclic adenosine monophosphate (cAMP) phosphodiesterase as shown with caffeine [12] . Nakayama et al. (2007) also showed that BF extracts activated thermogenesis in BAT and inhibited phosphodiesterase activity, resulting in weight loss [14] . Japanese women (BMI 36.5 ± 4.8 kg/m 2 ) with IGT and IR were randomized to receive either placebo (n = 40) or BF (24 mg/day) treatments (n = 41). After 24 wks, the BF group had significantly reduced bodyweight (90.8 ± 17.9 to 80 ± 10.3, p < 0.01) and abdominal visceral fat (197.6 ± 69.7 to 104.4 ± 28.0, p < 0.01), without decreases in resting metabolic rates (1986.2 ± 402.5 to 1821 ± 420.6). Whereas the placebo group showed body weight loss (90.3 ± 12.2 to 83.4 ± 13.4, p < 0.05), with no significant changes in abdominal visceral fat (177.2 ± 73.3 to 140.9 ± 60.4) [12] .
Capsinoids
Capsinoids are abundant in non-pungent chili peppers (Capsicum anuum L.; Solanacae or pepper fruit; variety CH-19 Sweet) (chemical structures 2). Watanabe et al. (2011) researched the effects of capsinoids, increased basal metabolism, fatty acid oxidation and decreased body fat. These effects are mediated by transient receptor potential channels (TRP) and the sympathetic nervous system [15] .
BAT is a site for cold-and diet-induced thermogenesis, and therefore may be a target for body fat management. Yoneshiro et al. (2013) conducted a 6wk, placebo-controlled study and reported that cold-induced thermogenesis (CIT) was increased after administration of capsinoids (9 mg/day) (200.0 ± 33.9 vs 81.0 ± 32.5 kcal/d) [16] . Because CIT is proportional to BAT activity, these data suggest capsinoidinduced recruitment of BAT.
Orally administered capsiate activates transient receptor potential cation channel, subfamily V, member 1 (TRPV1) receptors on vagal afferents in the gut with equal potency to capsaicin, and results in increased sympathetic efferent activity and thermogenesis in animals [17] .
Snitker et al. (2009) conducted a 12-wk, placebocontrolled, double-blind, randomized study in which 80 subjects (BMI 30.4 ± 2.4) were recruited and randomly assigned to capsinoid (6 mg/day) or placebo treatment groups. Capsinoids were well tolerated and mean ± SD weight changes of 0.9 ± 3.1 and 0.5 ± 2.4 kg were observed in capsinoid and placebo groups, respectively (p = 0.86). Abdominal adiposity was also significantly decreased (p = 0.049) in the capsinoid group [17] .
DHA/EPA
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are essential fatty acids (chemical structures 3). These essential omega-3 fatty acids are found in cold-water fish and are highly unsaturated, with 5 or 6 double bonds on their carbon chains. These polyunsaturated fats play important roles in human physiology 5 .
Inoue et al. (2013) suggested that the ratio of EPA to arachidonic acid (EPA/AA ratio) may have a major role in obesity. The EPA/AA ratio, but not the DHA/AA ratio, was cor- related with visceral fat accumulation among men (n = 134) [18] .
Some mechanisms by which EPA and DHA act against obesity have been proposed. Specifically, EPA is a ligand of PPAR and activates the expression of genes that encode key enzymes of fatty acid transport and -oxidation. EPA also improves glucagon like peptide-1 (GLP-1) levels and enhances GLP-1 secretion from intestinal cells by activating G-protein-coupled receptor 120 (GRP120) [19] . GLP-1 also improves insulin secretion and satiety, and moderates postprandial glucose levels. These actions of GLP-1 effectively facilitate visceral fat reduction. [20] .
Forskohlii (South Asian herb)
Coleus forskohlii (CF) is a native Indian coleus plant of the Lamiaceae family that grows wild in arid and semi-arid regions of India and Thailand (chemical structures 4) . The rhizome part of the perennial CF plant has been traditionally used in Ayurvedic medicine as a remedy for heart disease, and respiratory, gastrointestinal, and central nervous systems disorders [21] . The active ingredients forskolin and diterpene act directly on adenylatecyclase, which activates cAMP and stimulates fat catabolism in human adipose cells [22] . CF regulates thermogenic responses to food, increases basal metabolic rates, and increases utilization of body fat. Theoretically, increased release of fatty acids from adipose tissue may also increase thermogenesis, facilitate body fat loss, and increase lean body mass. Enhanced lipolysis is associated with increased use of fat energy, and enhances fat loss without muscle mass loss [23] . 
Garcinia Cambogia
Hydroxycitric acid is an anti-obesity active ingredient found in rinds from the Indian fruit Garcinia cambogia (GC). GC derived hydroxycitric acid (chemical structure 5) decreases the synthesis and secretion of very low density lipoprotein (VLDL) in the liver by inhibiting citrate lyase, which ensures the availability of cytosolic acetyl-CoA after mobilization of citrate from mitochondria. As a precursor of malonyl-CoA, acetyl-CoA is the major de novo substrate for fatty acid biosynthesis. Under conditions of decreased fat secretion from the liver, increased plasma chylomicron levels may compensate by providing lipids derived from dietary sources, potentially under the influence of the hormone leptin [24] . Finally, hydroxycitric acid competitively inhibits the extramitochondrial enzyme adenosine triphosphatecitrate (pro-3S)-lyase, which may inhibit de novo lipogenesis as a citrate cleavage enzyme. Taken together, these mechanisms suggest that GC may lower body weight and reduce fat mass in humans [25] .
Various supplements contain GC with other components. However, GC is investigated in only one clinical study. Namely, Hayamizu (2003) et al. performed a double-blind, randomized, placebo-controlled, parallel-group design trial of 44 subjects (GC, n = 18; placebo, n = 21) aged 20-65 years with visceral fat areas of >90 cm 2 . Subjects were randomly assigned to receive GC extract for 12 wks (1667.25 mg/9 tablets, containing 1000 mg of hydroxycitric acid). At 16 wk, the GC group had significantly reduced visceral, subcutaneous and total fat areas compared with placebo group (p < 0.001). However, neither body weight nor BMI were significantly lower in the GC group [26] .
Lactoferrin
Lactoferrin (LF) is an iron-binding glycoprotein found in exocrine secretions such as breast milk, tears, sweat, and saliva. It is accepted that LF is a protective factor that prevents attacks from exogenous bacteria and viruses. LF has been shown to influence master regulators of adipocyte dif- . Subjects consumed entericcoated LF (eLF) (300 mg/d as bovine LF) or placebo tablets for 8 wks and total visceral and subcutaneous fat areas were measured using computed tomography. In comparison with the placebo group, visceral fat area was significantly reduced in the eLF group ( 1.8 vs. 14.6 cm 2 , respectively, p = 0.009; ANCOVA). Decreases in body weight, BMI, and hip circumference in the eLF group ( 1.5 kg, 0.6 kg/m 2 , and 2.6 cm, respectively) were also significantly greater than those in placebo group (1.0 kg, 0.3 kg/m 2 , and 0.2 cm; p = 0.032, 0.013, and 0.041, respectively). There was also a tendency for a reduced waist circumference in the eLF group ( 4.4 cm) when compared with the placebo group ( 0.9 cm; p = 0.073) [28] .
L-Carnitine
L-Carnitine (LC) is a vitamin-like amino acid derivative (chemical structure 6) involved in metabolism of lipid and use of fat energy. LC promotes transport of long chain fatty acids across the selective inner membrane into the mitochondrial matrix for further -oxidation. In addition to endogenous supply from liver, kidney, and other organs, LC is also ingested from foods such as lean meat [29] . Wutzke et al. (2004) showed that oral administration of LC to healthy human subjects for 10 days significantly facilitated fatty acid oxidation, indicating that LC may be a limiting factor for fat catabolism. Oyanagi et al. (2011) showed protective effects of LC vs. free fatty acid against mitochondrial membrane disruption, resulting in sustainedoxidation functionally. These observations suggest that LC supplementation may attenuate obesity by improving rate limiting mitochondrial processes [30] [31] . 2 ) male subjects for a double-blind randomized placebo-controlled study. In this trial, low-dosage (500 mg/day) LC supplementation and motivation training for 4 wks resulted in significant body weight loss (82.0 ± 2.2 to 80.9 ± 1.8 kg, p < 0.01) and decreased serum triglyceride levels (218 ± 45 to 145 ± 42, p < 0.01) compared with nonmotivated placebo-treated subjects [32] .
Oligonol (Lychee polyphenol)
Oligonol is a lychee fruit-derived polyphenol that is oligomerized during manufacture of catechin-type monomers and proanthocyanidin oligomers (chemical structure 7). Diabetes-induced hepatic damage is occasionally observed in patients with metabolic syndrome. Oligonol has been shown to protect against hepatic damage by regulating oxidative stress and lipid metabolism in vitro and in vivo [33] . Ogasawara et al. (2010) demonstrated a mechanism for oligonolimproved lipid metabolism that involves the mitogen activated-protein kinase (MAPK) signaling pathway. Oligonol stimulated lipolysis in primary adipocytes by activating Ras and phosphorylated (Raf-1) and MEK1/2 independent of autocrine/paracrine interleukin 6 (IL6), leading to significant activation of ERK1/2 proteins and decreased secretion of IL-6 from adipocytes [34] .
Nishihira et al. (2009) performed a randomized doubleblind, placebo-controlled clinical trial of oligonol in 18 adult volunteers with abdominal circumference of >85 cm. Subjects were enrolled and divided into groups treated with 50 mg oligonol or placebo/d for 10 wks. Clinical parameters such as waist circumference (p < 0.01), subcutaneous fat area (p < 0.05) and visceral fat area (80.5 ± 45.8 to 68.6 ± 36.5 cm 2 , p < 0.05) were significantly decreased in the oligonol group compared with placebo treated subjects [35] .
Tea Catechin
Polyphenol bioactivities have recently become topical in medicine and cosmetics. Green tea, which has been consumed in Asian countries for centuries, contains lowmolecular-weight polyphenols comprising mainly flavanol (flavan-3-ol) monomers, which are referred to as catechins (chemical structure 8) [36] . Green tea components have been shown to affect PPAR signaling pathways. Lee et al. (2004) reported that green tea and its main constituent epigallocatechin gallate (EGCG) increased the activation of PPAR [37] . Tea catechins also suppressed adipocyte differentiation and downregulated PPAR and C/EBP [38] , which is a family of ligand-activated transcription factors of the nuclear receptor superfamily and is critical to fat metabolism and activation of PPARs. Nagao et al. (2005) investigated the effects of tea catechin in 38 healthy normal to overweight men. Subjects were divided into 2 groups with similar BMI and waist circumference distribution, and ingested 1 bottle of oolong tea/d containing 690 mg of catechins (green tea extract group; n = 17) or 1 bottle of oolong tea/d containing 22 mg of catechins (control group; n = 18). After 12 wks, the green tea extract group achieved significant reduction in body weight (p < 0.01; vs. placebo p < 0.05), BMI (p < 0.01; vs placebo p < 0.05), waist circumference (p < 0.01; vs placebo p < 0.05), body fat mass (p < 0.01; vs placebo p < 0.05), and subcutaneous fat area (p < 0.01; vs placebo p < 0.05). Changes in the concentrations of malondialdehyde-modified LDL were positively associated with changes in body fat mass and total fat area in the green tea extract group [36] . 7 .
DISCUSSION
Patients often inquire about anti-obesity supplements to medical professionals. However, due to lack of sufficient evidence, only few recommendations for anti-obesity supplements are possible. Nonetheless, most medical professionals fail to recognize the paucity of evidence for anti- obesity supplements in Japan. In addition, supplementsupplement and supplement-drug interactions remain largely unknown, despite the prevalent use of anti-hypertensive, anti-hyperlipidemia, and anti-diabetic drugs by obese patients.
Nonetheless, many people strive to decrease body weight using supplements that lack evidence. Thus, evidence-based research into the efficacy and safety of anti-obesity supplements is required for informed lifestyle management recommendations.
Accordingly, these products are marketed for weight reduction, but not for medical use, partly due to Japanese labeling regulations that prohibit health claims regarding antiobesity effects of products, but recognize foods for specified health use (FOSHU; TOKUHO in Japanese) 8 . These regulations allow companies to produce supplements without clinical evidence and make it difficult for consumers to assess whether or not products have evidence. To solve this problem, the Japanese government is considering deregulation of dietary supplement labeling, which may encourage provision of evidence for anti-obesity supplements in the Japanese market.
CONCLUSION
Despite expectations, many companies have produced clinical evidence for their products regardless of labeling regulations in Japan. To improve the precision of this study, we only listed 11 products for which clinical trials were published in English journals (Table 1) . However, in addition to these, we found 10 more products with clinical trial evidence published in Japanese or with evidence from experimental Table 4) . We expect that many companies will produce clinical evidence of international standard for their products in near future.
The Japanese market for dietary supplements is growing rapidly. However, the use of supplements remains more widespread in Western countries. Information regarding ingredients and products of supplements is more readily available in western counties, as indicated by the National Center for Complementary & Alternative Medicine (NCCAM) in America 9 . Thus, clinical evidence of supplement efficacy and safety should be more actively pursued in Japanese CAM.
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